Welcome to our dedicated page for Genelux news (Ticker: GNLX), a resource for investors and traders seeking the latest updates and insights on Genelux stock.
Genelux Corporation (NASDAQ: GNLX) is a late clinical-stage biopharmaceutical company in the immuno-oncology field, and this news page aggregates company announcements, clinical updates, and corporate developments related to its oncolytic immunotherapy programs. Genelux focuses on developing next-generation oncolytic vaccinia virus immunotherapeutic product candidates, led by its proprietary asset Olvi-Vec (olvimulogene nanivacirepvec).
News about Genelux frequently highlights progress in its clinical pipeline, including the Phase 3 OnPrime/GOG-3076 registrational trial in platinum-resistant/refractory ovarian cancer, the Phase 2 VIRO-25 trial in advanced or metastatic recurrent non-small cell lung cancer, and the Phase 1b/2 Olvi-Vec-SCLC-202 trial in recurrent or progressive small cell lung cancer. Company releases also describe interim data from these studies, such as observed anti-tumor activity, disease control rates, and tolerability of systemically administered Olvi-Vec in lung cancer settings.
In addition to clinical data, investors can find updates on public offerings of common stock, use of proceeds for research and development and clinical trial expenses, and governance-related items such as executive appointments and equity incentive plan changes. SEC-related disclosures, conference participation, and fireside chats with analysts are also common topics in Genelux’s news flow.
By following GNLX news, readers can track how Genelux advances its CHOICE™ platform-derived pipeline, how Olvi-Vec is being evaluated across multiple solid tumor indications, and how corporate actions support its late clinical-stage development strategy. This page provides a centralized view of the company’s press releases and public communications for those monitoring its progress in oncolytic viral immunotherapy.
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, reported Q2 2025 financial results and provided pipeline updates. The company's lead candidate Olvi-Vec is advancing in multiple clinical trials, with key data readouts expected. The Phase 3 OnPrime/GOG-3076 registrational trial in platinum-resistant/refractory ovarian cancer (PRROC) is progressing toward topline data in H1 2026.
Financial highlights include cash position of $28.1 million as of June 30, 2025, providing runway into Q3 2026. Q2 2025 resulted in a net loss of $7.5 million ($0.20 per share), compared to $6.6 million ($0.22 per share) in Q2 2024. The company strengthened its leadership team with Eric Groen joining as General Counsel and Head of Business Development.
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has appointed Eric Groen as General Counsel, Corporate Secretary, Chief Compliance Officer and Head of Business Development, effective July 1, 2025.
Groen brings over 20 years of experience in the life sciences industry, notably serving at Rani Therapeutics and Amgen, where he played a key role in the $10 billion Onyx Pharmaceuticals acquisition. As part of his appointment, Groen received an inducement award of 270,000 stock options at $2.83 per share, vesting over four years.
Genelux Corporation (NASDAQ: GNLX), a late clinical-stage immuno-oncology company, has announced its participation in the upcoming Citizens Life Sciences Conference in New York on May 7-8, 2025. CEO and Chairman Thomas Zindrick and CFO Matt Pulisic will engage in a fireside chat with Biotech Equity Research Managing Director Silvan Tuerkcan on May 8 at 1:30 p.m. ET. The discussion will focus on the company's clinical-stage programs and upcoming milestones.
The event will be accessible via webcast, with a replay available for 90 days on Genelux's IR page. The company will also conduct one-on-one meetings with institutional investors during the conference.
Genelux (NASDAQ: GNLX) reported its Q4 and full year 2024 financial results, highlighting key developments in its oncology pipeline. The company reached alignment with FDA on the approval pathway for Olvi-Vec in Platinum Resistant/Refractory Ovarian Cancer, with topline data expected in H1 2026.
In clinical developments, preliminary Phase 1b/2 data for Olvi-Vec in Advanced Small-Cell Lung Cancer showed a 71% disease control rate, with two partial responders and favorable safety profile. The company strengthened its financial position with a $10.5 million underwritten offering at $3.50 per share.
Financial highlights include:
- Cash position of $30.9 million as of December 31, 2024
- R&D expenses increased to $19.0 million from $12.8 million in 2023
- G&A expenses rose to $12.7 million from $11.6 million in 2023
- Net loss of $29.9 million ($0.95 per share) compared to $28.3 million ($1.16 per share) in 2023
Genelux (Nasdaq: GNLX) has announced the pricing of an underwritten offering of 3,000,000 shares of common stock at $3.50 per share, expected to raise gross proceeds of $10.5 million. The late clinical-stage immuno-oncology company plans to use the net proceeds for working capital and general corporate purposes, including the continued clinical development of Olvi-Vec.
The offering is expected to close on March 26, 2025, subject to customary closing conditions. Titan Partners Group, a division of American Capital Partners, is serving as the sole bookrunner for the offering. The securities are being offered through an effective shelf registration statement previously filed with the SEC.
Genelux and Newsoara BioPharma have announced promising preliminary data from their Phase 1b/2 trial of Olvi-Vec immunochemotherapy in platinum-relapsed/refractory small cell lung cancer patients. The trial showed a 71% disease control rate (5/7 patients), with two achieving partial responses.
Key highlights include:
- One participant achieved ~79% tumor reduction
- Three participants reached stable disease with tumor reductions of 24-29.2%
- All patients with disease control experienced reductions in all target lesions
- Treatment demonstrated favorable safety profile with mostly mild to moderate side effects
The data suggests Olvi-Vec's potential as a platinum resensitizing agent beyond ovarian cancer. The trial continues enrollment for dose escalation to determine the recommended intravenous dose for Phase 2.
Genelux (NASDAQ: GNLX) has announced a successful Type D meeting with the FDA regarding Olvi-Vec's approval pathway for treating platinum resistant/refractory ovarian cancer (PRROC). The FDA indicated that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval without requiring a separate confirmatory study.
The FDA specified that if the trial demonstrates a clinically meaningful progression-free survival (PFS) advantage without decreasing overall survival (OS), it could be sufficient for traditional approval. The company plans to report topline safety and efficacy data in the first half of 2026.
Genelux (NASDAQ: GNLX) has appointed Matthew Pulisic as its new Chief Financial Officer, effective January 30, 2025. Pulisic brings over 19 years of finance and commercial experience in the biopharmaceutical industry, having worked across the United States, Europe, and Asia.
Prior to joining Genelux, Pulisic served as Vice President of Finance at Arrowhead Pharmaceuticals, where he led planning and analysis and established a commercial manufacturing facility. He previously worked at Amgen in various finance roles, including Finance Director of Amgen Worldwide and Head of Capital Finance.
As part of his appointment, Pulisic received an inducement award of stock options to purchase 275,000 shares at $3.95 per share, vesting over four years with 25% vesting after one year and the remainder monthly over 36 months.
Genelux (NASDAQ: GNLX) has announced its participation in a virtual fireside chat with H.C. Wainwright & Co. on December 16, 2024. The company's President, CEO and Chairman Thomas Zindrick will engage in discussions moderated by Biotech Equity Research Analyst Emily Bodnar, starting at 11:00 a.m. ET.
The session will focus on the clinical program of Olvi-Vec, including its ongoing:
- Phase 3 registration trial in platinum resistant/refractory ovarian cancer (PRROC)
- Phase 1b/2 trial in small-cell lung cancer (SCLC)
- Phase 2 trial in non-small cell lung cancer (NSCLC)
The event will be accessible through registration, with a replay available for approximately 90 days on the company's IR page.